Upsala J Med Sci 95: 137-145, 1990 

Effects of Exogenous Adenosine in a Patient with 
Transplanted Heart. Evidence for Adenosine as a 

Messenger in Angina Pectoris 
Bo Lagerqvist', Christer SylvCn3, Gunnar Helmius', 

Anders Waldenstrom' 
Departments of Internal Medicine' and Diagnostic Radiology2, University Ho vita1 

Uppsala and Department of Internal Medicine3, Huddinge Academic H o s p i d ,  
Huddinge, Sweden 

ABSTRACT 

In this pilot study some cardiac effects of exogenous adenosine on the 
denervated heart were studied in a patient with transplanted heart since 3 
years. He was instrumented with catheters into the left coronary artery, 
the coronary sinus and the right ventricle. Adenosine was given in 
increasing doses intracoronarily, into the aorta at the diaphragmal level 
and into a peripheral vein. 

When given into the aorta pain was provoked dose-dependently and not 
different from a reference group. When given intracoronarily no pain was 
provoked except at the highest dose when a slight discomfort of the chest 
was provoked. After intravenous injection no pain was provoked in the 
chest or in adjacent structures. 

Coronary sinus flow increased dose-dependently and not different from the 
reference group. No increased heart rate response occurred after 
intravenous or intracoronary injections. Extensive degrees of sinus and A V  
nodal blockade occurred. 

In conclusion, the results are in keeping with a role for adenosine as a 
messenger between myocardial ischaemia and angina pectoris and cardiac 
sympathetic pressure response. The importance of innervation for proper 
sinus and AV nodal function was also illustrated. 

137 



INTRODUCTION 

Adenosine has been proposed to be a messenger between myocardial 
ischaemia and angina pectoris (10, 11, 7). During myocardial ischaemia 
adenosine is released in large quantities from myocardial cells into the 
interstitium (3). When adenosine is given as a bolus intravenously or 
intracoronarily a pain is provoked in the chest with radiations into 
adjacent parts of the body.This pain is reported by patients with 
ischaemic heart disease not to be different from their habitual angina 
pectoris (1 1,7). 
provoked in areas supplied by the artery. Adenosine induced pain response 
is attenuated by theophylline and increased irrespective of injection site 
by dipyridamole in keeping with activation of extracellular membrane 
bound adenosine receptors. 

When adenosine is given intraarterially pain is also 

Thus a series of experiments has not been able to contradict the 
hypothesis that adenosine is a messenger between myocardial ischaemia 
and angina pectoris. As a further attempt to test this hypothesis we found 
it pertinent to give adenosine to patients with transplanted heart as such 
a heart is considered to be denervated. It has however been reported that 5 
% of acute myocardial infarcts in transplants are accompanied by chest 
pain ( 6 ) .  In this preliminary report we describe effects of exogenous 
adenosine on pain, heart rate response, sinus and A V  nodal blocks and 
coronary vasodilation in a patient with a transplanted heart. 

MEMODS 

The patient being a 59 years old male was transplanted 3 years ago due to 
intractable heart failure on the basis of congestive csrdiomyopathy. He had 
experienced four rejections that were successfully treated. Current 
medication was cyclosporine and dipyridamole, and at the time of 
investigation he was in New York Heart Association functional class 1 - 1 1 .  
No dipyridamole was taken the last 24 hours before the investigation, 
which was made in connection with routine endomyocardial biopsy and 
selective coronary angiography. The study was accepted by the Ethic’s 
committee and the patient was fully informed. 

A Wilton-Webster coronary sinus flow catheter was introduced into the 
coronary sinus under fluoroscopic control, and the position was tested by 
injection of contrast medium. The coronary sinus blood flow was 

I38 



determined by the thermodilution technique (5). A pacing electrode was 
introduced via the left femoral vein into the apical region of the right 
ventricle. The electrode was connected with an external pacemaker with 
an on demand rate of 60/minute. 

After diagnostic coronary angiography, adenosine was given with a 7 F 
coronary-catheter in two arterial positions, first in the left coronary 
orifice, secondly in the descending aorta at the level of the diaphragm. The 
patient was unaware of which site of injection was used. Adenosine 
dilutions were made from a standard solution of 5.0 mg/ml in saline, 
prepared by the hospital pharmacy. Adenosine was given in 3.0 ml in doses 
of 0.1, 1.0, 2.5, 5.0 and 10 mg. A constant injection time of 10 seconds 
was chosen in order to make the results comparable with those of 
intravenous injection of adenosine. After the intraarterial injections, 
adenosine was given as a bolus into an antebrachial vein in doses of 2.5, 
5.0, 7.5 and 10 mg; the vein was thereafter flushed with 5 ml of saline. In 
each dose-response series an injection of saline alone was included, 
single-blind. At onset of pain the patient raised his left hand. When the 
maximum pain began to subside the hand was lowered half way, and when 
the pain had disappeared the hand was lowered to the supine position. 
These time instants were noted on the online recordings of coronary sinus 
flow and of ECG (chest leads), the speed of which was 25 mm/sec. The 
magnitude of maximal pain was rated according to the CR-10 scale 
designed by Borg (2). The patient was also asked ro uescribe the !ocaticn 
and the character of the pain. Before the next dose the patient was asked 
whether any pain or discomfort remained. If the patient did not wish to 
proceed further, the last dose given was taken as the maximum tolerable. 
Heart rate was calculated before injection and at the highest rate after 
injection. When there was no obvious increase in heart rate the 
calculations were made 30-40 seconds after injection or at least 10 
seconds after any sinus or AV block. 

In a reference group coronary angiography was performed in 7 male 
patients with angina pectoris. This group has been examined principally in 
the same way, as previously described for 6 of the 7 patients (7). 

S t a t i s t i c s  

Changes were compared to previously (7) reported reterence values. A 
value 

139 



differing more than 2 S.D. away from the reference material was 
considered statistical significant. 

Table 1. Pain, coronary sinus blood flow and heart rate response after 
injection of adenosine in the heart transplanted patient compared to a 
reference group (mean f S.D.). 

observed reference group 

Pain threshold (mg adenosine) 
lntracoronary injection 10.0 2.7 k3.3 
lntraaortic injection 1 .o 1.3 kO.9 
Intravenous injection no pain 3.6 51.3 

Pain threshold ratio 
I n t r a c o r o n a r y / l n t r a a o r t i c  1 0 2.1 + 2.5 

Time(sec) to start of pain (mean of all doses that gave pain) 
lntracoronary injection 16,2 19.7 k 5.8 
lntraaortic injection 14.3 + 2.8 15.9 f 4.2 
Intravenous injection 18,7 f 4.5 

Time(sec) to start of coronary sinus blood flow increase (mean of all 
adenosine injections) 

lntracoronary injection 2.8 k 1.2 1.8k 1.8 
Intravenous injection 22.0 _+ 5.7 13.2 i 5.3 

Coronary sinus blood flow increase in % 
lntracoronary injection(1 mg) 165 1!3 k 80 
Intravenous injection (5mg) 112 211 +lo9 

Increase in heart rate in % (mean of all adenosine injections) 
lntracoronary injection 3+2 26 +28 
lntraaortic injection 5+4 31 +19 
Intravenous injection 2k4 42 It24 

Time to maximum heart rate (sec) (mean of all adenosine injections) 
In tracoronary injection 56+24 40 f 1 7  
lntraaortic injection 35+7 24 + 4 
Intravenous injection 41 +8 40 + 7 

140 



RESULTS 

Provocation of Dain 

When given intracoronary adenosine provoked chest pain only at the 
highest dose (10 mg) as opposed to the reference group where pain was 
induced at 2.7f3.3 mg (meanf S.D.). Injection of adenosine into the aorta at 
the diaphragmal level followed the same dose-response relation as in the 
reference group and the pain was located to the chest and the diaphragmal 
area. The lowest dose of adenosine that gave pain (pain threshold) when 
injected into the aorta was of the same magnitude as in the reference 
group. When the pain thresholds (in mg of adenosine) between 
intracoronary and intraaortic injections were compared , the difference 
was more than 3 S.D. higher as when compared to the correspondingly ratio 
of the reference group.When the ratio of the score of pain induced by 
intracoronary and intraaortic injections in patient was compared to the 
corresponding ratio of the reference group the difference was more than 3 
S.D.. 

After intravenous injection of adenosine no chest pain was provoked, but 
after the two highest dosages our patient reported pain in the forehead. 
The patient experienced respiratory stimulation at dl dosages also in 
accordance with previous findings (1,12). 

Coronarv flow. 

Adenosine administration in the coronary artery and the antebrachial 
vein,but not into the aorta, resulted in increased coronary sinus blood flow 
with onset shortly after the onset of injection. The response did not differ 
from the reference values (table 1). The flow responses shown in table 1 
are after intracoronary and intravenous injection of 1 mg respectively 5 
mg adenosine. These doses were choosen because they were given to all of 
the tested subjects. 

Sinus and A V  nodal conduction and heart rate response. 

lntra aortic injection did not induce any conduction dcfects even at the 
highest dose given. After intracoronary injection of adenosine, except at 
the lowest dose (0.1 mg), SA arrest/blocks were seen. The duration of 

141 



Figure 1:Pain responses of different doses of adenosine. Pain 
response is graded according to the CR-10 Borg scale 

8 -  

6 -  

.- : 4 -  
n 

2 

0 

8 

Reference group 

;T- 
Heart transplanted patient 

- .  . I .  , 

6 

A. lntracoronary injection 

1 
i 

2 

0 
0 5 1 0  

Dose of adenosine (mg) 

B. lntraaortic injection 

Heart transplanted patient 

C 
m 
.- 
n 

0 5 1 0  
Dose of adenosine (mg) 

142 



bradycardia was proportional to the dose given and amounted to 32 
seconds after 1,0 mg adenosine and to 73 seconds at tbe highest dose (10 

Intravenous injection did not provoked SA arrest/block but resulted in A V  
block 11-111 with longer duration being 23 seconds at maximum dose and a 
dose dependent delay of onset (table 2). In the reference group no SA 
arrest/block developed, and only 2 out of 7 developed AV block after 
intravenous injection of adenosine, both at higher dosages, 10 and 1 5  mg 
and both with a duration of the block less than 5 seconds. 
The mean heart rate before each injection was for the transplanted patient 
92.9f5.6 m-1 and for the reference group 62.4k10.0 m - 1  

mg). 

Table 2. AV block after intravenous injection and SA arrest/block after 
intracoronary injection of adenosine.in to the heart transplanted patient 

Adenosine dose (mg) 

Intravenous : 
2 . 5  
5 . 0  
7.5 
1 0 . 0  

In tracornary: 
0.1 
1 .o 
2.5 
5 . 0  
1 0 . 0  

time after injection 
to block (sec) 

2 0  
21 
1 8  
1 5  

5 
3 
1 
0.5 

Duration of 
block (sec) 

3 
1 2  
1 7  
2 3  

0 
3 3  
4 4  
6 5  
7 4  

After the disappearance of sinus and A V  block the heart rate returned to 
the baseline (table 1). 

DISCUSSION 

The main finding in this case report on a heart transplanted patient is that 
higher doses of intracoronary adenosine were needed to produce pain 
comparable to the reference group. In contrast, intraaortic administration 
provoked similar degrees of pain in our patient compared to the reference 
group. This was expected because the neurons responsible for the pain, 
when adenosine was given into the aorta at the diaphragmal level, should 
not be influenced by the transplantation operation itself. Although the 
provocation of pain was greatly attenuated when given intracoronarily, 

9t-908572 143 



even at the highest dose of intracoronary adenosine only a moderate pain 
was reported and located to the chest. This pain is less likely to have 
originated from the pulmonary vascular bed as no pain was reported after 
intravenous injection. The most probable explanation is that the pain 
originates from the residual atrial tissue with intact original innervation. 
Another possibility for pain induction could be recirculation of adenosine 
through Thebesian veins and subsequent activation of mediastinal neurons. 
An alternative possibility is activation of cardiac neurons shown to grow 
into a canine experimental heart transplant model (9). Furthermore, about 
5 Yo of patients with transplanted hearts experienced chest pain in 
association with acute myocardial infarction (6). Our observations 
therefore strongly corroborate adenosine as a messenger between 
myocardial ischaemia and chest pain. 

Coronary sinus flow increased to the same degree as in the reference 
group both after intracoronary and intravenous injections. Also the early 
onset of flow increase was similar to the reference group. These 
observations indicate that adenosine induced increase of coronary flow is 
independent of coronary vascular innervation and in keeping with a direct 
effect of adenosine on the vascular tone (4). 
The normally seen increase in heart rate of about 25 ?Ao following 
intravenous and intracoronary injections of adenosine were absent in this 
transplanted patient. This observation indicate that the increased heart 
rate is mediated via cardiac innervation. This heart rate response was 
previously reported to be associated with both increased systolic and 
diastolic blood pressures (8). These observations could possibly relate to 
the paradoxical increase of heart rate and blood pressure in anterior acute 
myocardial infarction that consequently could be mediated by 
ischaemically released adenosine which in its turn sensitizes sympathetic 
cardiac nerves resulting in a syrnpatho-adrenergic res2onse. 

ACKNOWLEDGEMENTS 

This study was supported by the Swedish Heart and Lung Foundation, the 
Groschinsky Foundation and Soderbergs Foundations 

REFERENCES 

1 Berne R.M., DiMarco J.P. & Belardinelli L. Drornotropic effects of 
adenosine and adenosine antagonists in the treatment of cardiac 

144 



arrhytmias involving the atrio-ventricular node. Circulation 69: 11 95-7, 
1984. 
2 Borg G.: A category scale with ratio properties for intermodal and 
interindividual comparisons. In: Psychophysical judgement and the 
progress of perception (ed H-G. Geissler and P. Petzold ), pp 25-34. VEB 
Deutscher Verlag der Wissenschaften, Berlin, 1982. 

3 Edlund A . ,  Fredholm B.B., Patrinani P., Patron0 C. & Wennmalm A . ,  
Wennmalm M.: Release of two vasodilatators - adenosine and prostacyclin 
- from isolated rabbit heart during controlled hypoxia. J Physiol 340: 
487-501, 1983. 

4 Fredholm B.B. & Sollevi A.: Cardiovascular effects of adenosine. Clin 
Physiol 6 :  1-21, 1986. 

5 Ganz W., Tamura K., Marcus HS., Donoso R., Yoshida S. & Swan HJC. 
Measurement of coronary sinus blood flow by continuous thermodilution in 
man. Circulation 44: 181-95, 1971. 

6 Gao S.Z., Schroeder J., Hunt S., Billingham M. & Stinson E.: Myocardial 
infarction in cardiac transplant patients. Circulation 78: 11-438, 1988. 

7 Lagerqvist B., Sylven C., Beermann B., Helmius G. & Waldenstrom A.: 
lntracoronary adenosine causes angina pectoris like pain - an inquiry intc 
the nature of visceral pain. Cardiovasc Res 24:.609-13, 1990. 

8 Longhurst J.C.: Cardiac receptors:Their function in health and disease. 
Prog Cardiovasc Dis 27: 201-22, 1984. 

9 Mohanty P.K., Thames M.D., Capehart J.R., Kawaguchi A,, Ballon B. & Lower 
R.R. Afferent reinervation of the autotransplanted heart in dogs. J Am Coll 
Cardiol 7: 414-8, 1986. 

10 Sylven C., Beermann B., Jonzon B. & Brandt R.: Angina pectoris-like pain 
provoked by intravenous adenosine in healthy volunteers. Br Med J 293: 
227-30, 1986. 

11 Sylven C.: Angina pectoris. Clinical characteristics, neurophysiological 
and molecular mechanisms. Pain 36: 145-67, 1989. 

12 Watt A.H. & Routledge P.A. Adenosine stimulates respiration in man. Br 
J clin Pharrnac 20: 503-6, 1985. 

Address for reprints: 
Dr Anders Waldenstrom 
Dept. of Medicine 
University Hospital 
s-751 85 Uppsala, Sweden 

10 - 908572 145